An Intermediate Expanded Access Program (EAP) evaluating short-term access to migalastat for patients who are on enzyme replacement therapy and meet EAP requirements.

Trial Profile

An Intermediate Expanded Access Program (EAP) evaluating short-term access to migalastat for patients who are on enzyme replacement therapy and meet EAP requirements.

Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Migalastat (Primary)
  • Indications Fabry's disease
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 New trial record
    • 28 Nov 2016 According to an Amicus Therapeutics media release, this trial will generate additional data which will support regulatory approval of migalastat for Fabry disease in the USA.
    • 28 Nov 2016 According to an Amicus Therapeutics media release, this program expected to initiate in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top